Start / Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation / 167 how generative ai is revolutionizing biotech regulatory compliance with abhijeet satwekar part 1

Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation

167: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 1

14 min • 1 juli 2025

Ever feel like you’re drowning in an ocean of constantly shifting regulatory guidelines? The world of biotech is a whirlwind of evolving standards, making compliance not just a headache, but sometimes the stumbling block between life-changing therapies and the patients who need them. But what if artificial intelligence could turn regulatory chaos into your biggest competitive advantage?

In this episode, David Brühlmann sits down with Abhijeet Satwekar, Innovation Manager at Merck KGaA’s Global Analytical Development. Abhijeet shares how he’s pioneering the use of generative AI, not as a hype machine, but as a practical, transformative tool for regulatory compliance in biotech. With over a decade navigating analytics, digitalization, and collaborative tech adoption at a major pharma leader, Abhijeet knows what it takes to connect industry stakeholders, harness new technologies, and turn business operations into streamlined, value-generating systems.

Here are three reasons you won’t want to miss this episode:

Generative AI as a Compliance Powerhouse: Discover how AI is being harnessed to analyze, extract, and compare complex regulatory requirements across different countries, cutting through ambiguous language and shifting specifications - so you don’t have to.
Reducing Regulatory Bottlenecks: The days of manually reconciling guideline documents and updating baselines with every regulatory change are numbered. Learn how generative AI accelerates multi-guideline comparison, saving teams countless hours and reducing the risk of costly errors and delays.
A Blueprint for Digital Transformation: Abhijeet reveals how Merck is moving from proof-of-concept to operational reality, building collaborative teams that bridge IT, analytics, regulatory, and quality to bring valuable digital tools into daily practice.

Curious if your team could automate away regulatory headaches? Listen in and get inspired to tackle your toughest compliance challenges - before your competitors do.

Connect with Abhijeet Satwekar:

LinkedIn: https://www.linkedin.com/in/abhijeetsatwekar

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing development: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Support the show

Senaste avsnitt

172: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 2

17 juli | 20 min

171: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 1

15 juli | 21 min

170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 2

10 juli | 23 min

169: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 1

8 juli | 26 min

168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 2

3 juli | 25 min

167: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 1

Senaste avsnitt

172: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 2

171: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 1

170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 2

169: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 1

168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 2

167: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 1

166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It) - Part 2

165: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It) - Part 1

164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf - Part 2

163: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf - Part 1

162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 2

161: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 1

160: The Ultimate Guide to Accelerating Perfusion Process Development Using 96-Deep-Well Plates with Tom Valentin - Part 2

159: The Ultimate Guide to Accelerating Perfusion Process Development Using 96-Deep-Well Plates with Tom Valentin - Part 1

158: How to Detect Endotoxins Without Bleeding a Single Horseshoe Crab with Anika Hoffmann - Part 2

157: How to Detect Endotoxins Without Bleeding a Single Horseshoe Crab with Anika Hoffmann - Part 1

156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook

155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything

154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos - Part 2

153: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos - Part 1

152: Is an Indian CDMO the Right Move for Your Biologics Pipeline? with Abdelaziz Toumi - Part 2

151: Is an Indian CDMO the Right Move for Your Biologics Pipeline? with Abdelaziz Toumi - Part 1

150: How to Leverage AI in Media Development Without Sacrificing Process Understanding with Tom Fletcher - Part 2

149: How to Leverage AI in Media Development Without Sacrificing Process Understanding with Tom Fletcher - Part 1

148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir - Part 2

147: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir - Part 1

146: Beyond ELISA: The 10-Minute Immunoassay Enabling Real-Time Bioprocess Control with Bruno Oesch - Part 2

145: Beyond ELISA: The 10-Minute Immunoassay Enabling Real-Time Bioprocess Control with Bruno Oesch - Part 1

144: The Future of Biotech: Making Biotherapeutics More Accessible Faster

143: Bioprocess Breakthroughs: How Smart Bioprocessing Is Democratizing Life-Saving Treatments

142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor - Part 2

141: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor - Part 1

140: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 2

139: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 1

138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 2

137: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 1

136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)

135: Beyond Breakthroughs: Making Biotherapeutics Affordable for All

134: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 2

133: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 1

132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani - Part 2

131: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani - Part 1

130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 2

129: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 1

128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 2

127: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 1

126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 2

125: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 1

124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 2

123: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 1

122: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 2

121: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 1

120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 2

119: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 1

118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough - Part 2

117: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough - Part 1

116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 2

115: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 1

114: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 2

113: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 1

112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 2

111: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 1

110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 2

109: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 1

108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 2

107: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 1

106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 2

105: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 1

104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 2

103: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 1

102: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 2

101: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 1

100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 2

99: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 1

98: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 2

97: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 1

96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 2

95: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 1